c-myc Amplifications in primary breast carcinomas and their local recurrences

Objective: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. Methods: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. Results: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. Conclusions: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.

[1]  F. Vicini,et al.  Does local recurrence affect the rate of distant metastases and survival in patients with early‐stage breast carcinoma treated with breast‐conserving therapy? , 2003, Cancer.

[2]  C. Isaacs,et al.  New prognostic factors for breast cancer recurrence. , 2001, Seminars in oncology.

[3]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[4]  C. Perou,et al.  MYC Is Amplified in BRCA1-Associated Breast Cancers , 2004, Clinical Cancer Research.

[5]  R. Jäger,et al.  Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice , 1997, Oncogene.

[6]  L. Holmberg,et al.  Time trends in the results of breast conservation in 4694 women. , 2001, European journal of cancer.

[7]  R. Dickson,et al.  c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells , 2003, British Journal of Cancer.

[8]  P. Lichter,et al.  Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. , 1995, Methods in enzymology.

[9]  S. Devries,et al.  Genetic alterations in ERBB2-amplified breast carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Takafumi Nishizaki,et al.  Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[11]  J. Coebergh,et al.  Local recurrence after breast conservation therapy for early stage breast carcinoma , 1999 .

[12]  J. Engel,et al.  Determinants and prognoses of locoregional and distant progression in breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[13]  A. Legorreta,et al.  Diagnosis, Clinical Staging, and Treatment of Breast Cancer: A Retrospective Multiyear Study of a Large Controlled Population , 2004, American journal of clinical oncology.

[14]  S. Aulmann,et al.  C-myc oncogene amplification in ductal carcinoma in situ of the breast , 2002, Breast Cancer Research and Treatment.

[15]  J. Isola,et al.  Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples , 2001, Laboratory Investigation.

[16]  Daniel J Schaid,et al.  ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers , 2004, Genes, chromosomes & cancer.

[17]  M. J. van de Vijver,et al.  Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.

[18]  R. Dickson,et al.  Overexpression of c-Myc Alters G1/S Arrest following Ionizing Radiation , 2002, Molecular and Cellular Biology.

[19]  Rodrigo Arriagada,et al.  Prognostic factors for death after an isolated local recurrence in patients with early‐stage breast carcinoma , 2002, Cancer.

[20]  A. Magener,et al.  Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. , 1998, European Journal of Cancer.

[21]  F. Orr,et al.  C‐myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells , 2002, International journal of cancer.

[22]  N. Lee,et al.  Identification of c-myc responsive genes using rat cDNA microarray. , 2000, Cancer research.

[23]  R. Simmons,et al.  Locally recurrent breast cancer after conservation therapy. , 2005, American journal of surgery.

[24]  D. Rimm,et al.  Molecular markers for prognosis after isolated postmastectomy chest wall recurrence , 2004, Cancer.

[25]  Norhanom Abdul Wahab,et al.  Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. , 2002, International journal of molecular medicine.

[26]  R. Dickson,et al.  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models , 2000, Oncogene.

[27]  P. Regitnig,et al.  Microsatellite analysis of breast carcinoma and corresponding local recurrences , 2002, The Journal of pathology.

[28]  R. Cardiff,et al.  Transgenic oncogene mice. Tumor phenotype predicts genotype. , 1991, The American journal of pathology.

[29]  L. Holmberg,et al.  Risk factors for local recurrence after breast‐conserving surgery , 2003, The British journal of surgery.

[30]  J. Coebergh,et al.  Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). , 1999, Cancer.

[31]  B. Dutrillaux,et al.  Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: Relation to morphology, cell proliferation and expression of breast cancer‐related genes , 2000, International journal of cancer.

[32]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[33]  W. Remmele,et al.  Relation of elastosis to biochemical and immunohistochemical steroid receptor findings, Ki-67 and epidermal growth factor receptor (EGFR) immunostaining in invasive ductal breast cancer , 2005, Virchows Archiv A.

[34]  P. Lichter,et al.  Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. , 1992, Human molecular genetics.

[35]  T. Ried,et al.  Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability , 1998, Oncogene.